Opioid agents have been shown to protect against tissue damage caused by hypoxia/reperfusion, an event which has a significant reactive-oxygen-species (ROS) involvement. We have investigated the potential anti-inflammatory activity of three opioid agonists, DAMGO, DPDPE and U50488 in rat skin inflammation induced by the ROS hydrogen peroxide. The model involves the intradermal injection of the enzyme glucose oxidase which converts glucose to D-gluconic acid and H2O2 which is locally released. Following injection, a well-delineated inflammatory response develops rapidly, is maximal at 5 h and still measurable after 48 h. Co-administration of the Δ or ĸ opioid agonists DPDPE or U50488 (7.5-60 µg per site) significantly reduced the inflammation, in a dose-dependent manner, for periods of up to 3 h for DPDPE, and up to 5 h with U50488. The µ-opioid agonist DAMGO (7.5-60 µg per site) was ineffective. Co-administration of the opioid antagonist naltrexone (120 µg) partially reversed the anti-inflammatory effects of DPDPE and U50488. We conclude that the Δ and ĸ opioid receptor agonists DPDPE and U50488 are able to inhibit ROS-induced skin inflammation and that this may have clinical implications.

Keywords:
Opioid agonists, DAMGO, DPDPE, U50488, Reactive oxygen species, Skin inflammation
This content is only available via PDF.
© 1996 S. Karger AG, Basel
1996
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.